Efficacy of DHMEQ, a NF-κB Inhibitor, in Islet Transplantation: I. HMGB1 Suppression by DHMEQ Prevents Early Islet Graft Damage

被引:23
|
作者
Kuraya, Daisuke [1 ]
Watanabe, Masaaki [1 ]
Koshizuka, Yasuyuki [1 ]
Ogura, Masaomi [1 ]
Yoshida, Tadashi [1 ]
Asahi, Yoh [1 ]
Kamachi, Hirofumi [1 ]
Nakamura, Takashi [2 ]
Harashima, Hideyoshi [2 ]
Ozaki, Michitaka [1 ]
Umezawa, Kazuo [3 ]
Matsushita, Michiaki [1 ]
Yamashita, Kenichiro [4 ]
Todo, Satoru [4 ]
机构
[1] Hokkaido Univ, Sch Med, Dept Surg 1, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0608638, Japan
[3] Aichi Med Univ, Dept Mol Target Med Screening, Nagakute, Aichi 48011, Japan
[4] Hokkaido Univ, Sch Med, Dept Transplant Surg, Sapporo, Hokkaido 0608638, Japan
关键词
DHMEQ; Early graft loss; Nuclear factor-kappa B; Pancreatic islet transplantation; MOBILITY GROUP BOX-1; INTRAPORTAL TRANSPLANTATION; NUCLEAR TRANSLOCATION; PANCREATIC-ISLETS; INTERFERON-GAMMA; CELL-ACTIVATION; TISSUE FACTOR; DEHYDROXYMETHYLEPOXYQUINOMICIN; LANGERHANS; PROTEIN;
D O I
10.1097/TP.0b013e31829b0744
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Pancreatic islet transplantation (PITx) is an attractive treatment option for restoring appropriate glucose homeostasis in type 1 diabetes patients. Although islet grafts can successfully engraft after PITx, large numbers of islet grafts are required mainly because immune reactions, including inflammation, destroy islet grafts. In these processes, nuclear factor (NF)-kappa B plays a central role. We hypothesized that the inhibition of NF-kappa B activation would ameliorate inflammatory responses after PITx and aid successful engraftment. Methods. To test this hypothesis, a newly developed NF-kappa B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), was used on a syngeneic mouse PITx model. One hundred seventy-five islets from C57BL/6 (B6) mice were transplanted into streptozotocin-induced diabetic B6 mice. The recipient mice were administered DHMEQ for 1, 2, or 3 days after PITx. The underlying mechanisms of DHMEQ on islet graft protection were investigated in an in vitro coculture model of pancreatic islets and macrophages. Results. With a vehicle treatment, only 11.1% of the islet-recipients achieved normoglycemia after PITx. In sharp contrast, DHMEQ treatment markedly improved the normoglycemic rate, which was associated with the suppression of serum high mobility group complex-1 (HMGB1) and proinflammatory cytokines, including tumor necrosis factor-alpha, monocyte chemoattractant protein-1, macrophage inflammatory protein-1A, interleukin-1 beta, and interleukin-6, after PITx. In a murine macrophage-like cell line, DHMEQ inhibited HMGB1-driven activation and proinflammatory cytokine secretion and further prevented death isolated islets after coculture with these activated macrophages. Conclusions. Inhibition of NF-kappa B activation by DHMEQ after PITx reduces the HMGB1-triggered proinflammatory responses and results in engraftment of transplanted islets even with fewer islet grafts.
引用
收藏
页码:445 / 453
页数:9
相关论文
共 5 条
  • [1] Efficacy of DHMEQ, a NF-κB Inhibitor, in Islet Transplantation: II. Induction DHMEQ Treatment Ameliorates Subsequent Alloimmune Responses and Permits Long-Term Islet Allograft Acceptance
    Watanabe, Masaaki
    Yamashita, Kenichiro
    Kamachi, Hirofumi
    Kuraya, Daisuke
    Koshizuka, Yasuyuki
    Shibasaki, Susumu
    Asahi, Yoh
    Ono, Hitoshi
    Emoto, Shin
    Ogura, Masaomi
    Yoshida, Tadashi
    Ozaki, Michitaka
    Umezawa, Kazuo
    Matsushita, Michiaki
    Todo, Satoru
    TRANSPLANTATION, 2013, 96 (05) : 454 - 462
  • [2] Prevention of Graft Failure Caused by IBMIR with a Novel NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ) after Intraportal Islet Transplantation in Mice.
    Kuraya, Daisuke
    Kamachi, Hirofumi
    Watanabe, Masaaki
    Koshizuka, Yasuyuki
    Nakakimura, Shigeru
    Ozaki, Michitaka
    Umezawa, Kazuo
    Yamashita, Kenichiro
    Matsushita, Michiaki
    Todo, Satoru
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 355 - 355
  • [3] Donor pretreatment with a novel NF-kB inhibitor, DHMEQ can alleviate the graft damage in syngenic marginal islet transplantation
    Takahashi, Tohru
    Matsumoto, Shuichiro
    Tsuruga, Yosuke
    Kasai, Hironori
    Watanabe, Masaaki
    Ozaki, Michitaka
    Furukawa, Hiroyuki
    Matsushita, Michiaki
    Umezawa, Kazuo
    Todo, Satoru
    XENOTRANSPLANTATION, 2007, 14 (05) : 479 - 479
  • [4] DHMEQ, a New NF-κB Inhibitor, Suppresses Innate and Subsequent Allo-Immune Responses, and Permits a Long-Term Allogeneic Islet Engraftment Together with Tacrolimus
    Watanabe, Masaaki
    Yamashita, Kenichiro
    Kamachi, Hirofumi
    Kuraya, Daisuke
    Koshizuka, Yasuyuki
    Shibasaki, Susumu
    Ozaki, Michitaka
    Umezawa, Kazuo
    Matsushita, Michiaki
    Todo, Satoru
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 3 - 3
  • [5] Islet Transplantation Attenuating Testicular Injury in Type 1 Diabetic Rats Is Associated with Suppression of Oxidative Stress and Inflammation via Nrf-2/HO-1 and NF-κB Pathways
    Zhu, Xiandong
    Guo, Feixia
    Tang, Hengjie
    Huang, Chongchu
    Xie, Gangyin
    Huang, Tingting
    Li, Yonglin
    Liu, Chengyang
    Wang, Hongwei
    Chen, Bicheng
    JOURNAL OF DIABETES RESEARCH, 2019, 2019